59489-31-5 Usage
Uses
Used in Pharmaceutical Industry:
2,7-Dichloro-quinoxaline is used as a key intermediate in the synthesis of various pharmaceutical compounds for its versatile chemical properties and reactivity. It plays a crucial role in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, 2,7-dichloro-quinoxaline is utilized as a building block for the creation of complex organic molecules. Its unique structure allows for a wide range of chemical reactions, making it a valuable component in the synthesis of specialty chemicals and materials.
Used in Research and Development:
2,7-Dichloro-quinoxaline is employed in research and development settings to explore its chemical properties and potential applications. It serves as a model compound for studying the reactivity and behavior of heterocyclic compounds, contributing to the understanding of chemical reactions and mechanisms.
Used in Environmental and Safety Studies:
Given its potential hazards and environmental impact, 2,7-dichloro-quinoxaline is also used in studies focused on environmental safety and chemical management. These studies aim to develop guidelines for safe handling, disposal, and mitigation of risks associated with its use in various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 59489-31-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,4,8 and 9 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 59489-31:
(7*5)+(6*9)+(5*4)+(4*8)+(3*9)+(2*3)+(1*1)=175
175 % 10 = 5
So 59489-31-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H4Cl2N2/c9-5-1-2-6-7(3-5)12-8(10)4-11-6/h1-4H
59489-31-5Relevant academic research and scientific papers
Antitumor compositions and methods of treatment
-
, (2008/06/13)
This invention provides certain sulfonamidoquinoxaline derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these sulfonamidoquinoxaline derivatives, in combination with a carrier, diluent or excipient.
